Okay, let me tackle this question. The question is about the reaction that requires HMG-CoA reductase activity. First, I need to recall what HMG-CoA reductase does. I remember it's a key enzyme in cholesterol synthesis. The pathway starts with acetyl-CoA, which goes through various steps to form mevalonate. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate, and that's a rate-limiting step.

So the correct reaction should be HMG-CoA → Mevalonate. Now, looking at the options, the correct answer would be the one that states this conversion. The other options might involve different reactions in the pathway. Let's think about the other enzymes. For example, HMG-CoA synthase is involved in ketone body synthesis, not cholesterol. Also, there's the conversion of mevalonate to other intermediates, but those don't involve HMG-CoA reductase.

Wait, the options might include reactions like Acetyl-CoA to HMG-CoA, which is part of the pathway but not catalyzed by reductase. Another possible wrong option could be the conversion of mevalonate to isopentenyl pyrophosphate, which is done by other enzymes. Also, maybe a reaction in a different pathway like fatty acid synthesis. So the incorrect options would be those that are either steps after mevalonate or part of a different pathway altogether.

The clinical pearl here is that HMG-CoA reductase is the target of statins, which inhibit cholesterol synthesis. Students should remember that statins work here to lower cholesterol. Also, the reaction is crucial because it's the rate-limiting step, so any question about cholesterol synthesis inhibitors will hinge on this enzyme.

**Core Concept**
HMG-CoA reductase catalyzes the conversion of **HMG-CoA (3-hydroxy-3-methylglutaryl-CoA)** to **mevalonate**, a rate-limiting step in **cholesterol biosynthesis**. This reaction occurs in the cytoplasm and is the primary target of **statins** (e.g., atorvastatin) for reducing cholesterol production.

**Why the Correct Answer is Right**
HMG-CoA reductase is the **rate-limiting enzyme** in the mevalonate pathway. It reduces HMG-CoA using **NADPH** to form mevalonate, which is essential for synthesizing cholesterol, isoprenoids, and other vital molecules. This reaction is a classic exam topic because it is the **main target for lipid-lowering therapy** and is tightly regulated by feedback inhibition (e.g., by cholesterol).

**Why Each Wrong Option is Incorrect**
**Option A:** If describing **HMG-CoA synthase** (e.g., "Acetyl-CoA → HMG-CoA"), it is incorrect because this enzyme is involved in **ketogenesis**, not cholesterol synthesis.
**Option B:** If describing **mevalonate kinase** (e.g., "Mevalonate → Phosphomevalonate"), it is incorrect because this step occurs *after* HMG-CoA reductase in the pathway.
**Option C:** If describing **fatty acid synthesis** (e.g.,

✓ Correct Answer: A. β-hydroxy–β-methyl glutaryl COA → Mevalonic acid